Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Premarin versus clobetasol + premarin for vaginal disease after hematopoietic stem cell transplantation
IRCT20160615028486N3Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of conjugated estrogens and clobetasol in graft-versus-host disease (GVHD) and No canonical full name exists for "vaginal disease," as it is not a recognized individual medical diagnosis (2 arms), sponsored by Tehran University of Medical Sciences. Started Jul 2022; status: completed.
02
Drugs
conjugated estrogensclobetasol
03
Conditions
graft-versus-host disease (GVHD)No canonical full name exists for "vaginal disease," as it is not a recognized individual medical diagnosis.
Beyond the preview
Go deeper on IRCT20160615028486N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160615028486N3.